Dr. Jeroen de Groot is Senior Director at Charles River Laboratories. He received his Master’s degree (cum laude) in Biology from the Leiden University and his PhD from Utrecht University Medical Center (dept. of Rheumatology) on the molecular mechanisms underlying osteoarthritis. Subsequently he joined the Netherlands Organization for Applied Scientific Research (TNO), where he held various research and management positions over a period of twelve years. Initially he focused on in vitro and in vivo models as well as translational biomarkers for inflammatory & degenerative diseases. Later on in his career, he managed the department of pharmacokinetics and human studies. In November 2013, Jeroen joined Galapagos as Director of Cell Biology, overseeing their contract research programs, which were acquired by Charles River in 2014. Since December 2015, as Senior Director & Site Director, he leads the Charles River Leiden site in the Netherlands, which focuses on complex cell biology, target discovery and validation programs as well as phenotypic screening projects across therapeutic areas. During his career, Jeroen published >100 scientific papers, reviews and book chapters, and supervised 6 PhD students. He is a member of the Orthopaedic Research Society, the American College of Rheumatology, and the Osteoarthritis Research Society International.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, to support clients from target identification through preclinical development. Utilizing our broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
This project focuses on the application of human organoid technology in industrial drug discovery. The purpose of this project is to develop human organoid-based infectious disease models and to apply these in drug screening using a variety of technologies (e.g. (stem) cell culture, high throughput screening, virology/infectious disease, and high content imaging).